Literature DB >> 30845035

Usually, Selectively, or Rarely Resurfacing the Patella During Primary Total Knee Arthroplasty: Determining the Best Strategy.

Alistair J Maney1, Chuan K Koh2, Christopher M Frampton3, Simon W Young4.   

Abstract

BACKGROUND: Surgeons may "usually" resurface the patella during total knee arthroplasty (TKA), "rarely" resurface, or "selectively" resurface on the basis of certain criteria. It is unknown which of these 3 strategies yields superior outcomes. Utilizing New Zealand Joint Registry data, we investigated (1) what proportion of surgeons employs each of the 3 patellar resurfacing strategies, (2) which strategy is associated with the lowest overall revision rate, and (3) which strategy is associated with the highest 6-month and 5-year Oxford Knee Score (OKS).
METHODS: Two hundred and three surgeons who performed a total of 57,766 primary TKAs from 1999 to 2015 were categorized into the 3 surgeon strategies on the basis of how often they resurfaced the patella during primary total knee arthroplasty; with "rarely" defined as <10% of the time, "selectively" as ≥10% to ≤90%, and "usually" as >90%. For each strategy, the cumulative incidence of all-cause revision was calculated and utilized to construct Kaplan-Meier survival curves. The mean 6-month and 5-year postoperative OKS for each group were utilized for comparison.
RESULTS: Overall, 57% of surgeons selectively resurfaced, 37% rarely resurfaced, and 7% usually resurfaced. The usually resurfacing group was associated with the highest mean OKS at both 6 months (38.57; p < 0.001) and 5 years postoperatively (41.34; p = 0.029), followed by the selectively resurfacing group (6-month OKS, 37.79; 5-year OKS, 40.87) and the rarely resurfacing group (6-month OKS, 36.92; 5-year OKS, 40.02). Overall, there was no difference in the revision rate per 100 component years among the rarely (0.46), selectively (0.52), or usually (0.46) resurfacing groups (p = 0.587). Posterior-stabilized TKAs that were performed by surgeons who selectively resurfaced had a lower revision rate (0.54) than those by surgeons who usually resurfaced (0.64) or rarely resurfaced (0.74; p < 0.001).
CONCLUSIONS: Usually resurfacing the patella was associated with improved patient-reported outcomes, but there was no difference in overall revision rates among the 3 strategies. LEVEL OF EVIDENCE: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.

Entities:  

Mesh:

Year:  2019        PMID: 30845035     DOI: 10.2106/JBJS.18.00389

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  4 in total

Review 1.  Effect of patella resurfacing on functional outcome and revision rate in primary total knee arthroplasty (Review).

Authors:  Sorin Radu Fleaca; Cosmin Ioan Mohor; Horatiu Dura; Radu Chicea; Calin Mohor; Adrian Boicean; Mihai Dan Roman
Journal:  Exp Ther Med       Date:  2021-12-01       Impact factor: 2.447

2.  Clinical effectiveness of patellar resurfacing, no resurfacing and selective resurfacing in primary total knee replacement: systematic review and meta-analysis of interventional and observational evidence.

Authors:  Michal Grela; Matthew Barrett; Setor K Kunutsor; Ashley W Blom; Michael R Whitehouse; Gulraj S Matharu
Journal:  BMC Musculoskelet Disord       Date:  2022-10-22       Impact factor: 2.562

3.  CORR Insights®: Does Circumferential Patellar Denervation Result in Decreased Knee Pain and Improved Patient-reported Outcomes in Patients Undergoing Nonresurfaced, Simultaneous, Bilateral TKA?

Authors:  Michael D Ries
Journal:  Clin Orthop Relat Res       Date:  2020-09       Impact factor: 4.755

4.  Rare primary patellar resurfacing does not lead to more secondary patellar resurfacing: analysis of 70,014 primary total knee arthroplasties in the Dutch Arthroplasty Register (LROI).

Authors:  Bart J Robben; Astrid J De Vries; Anneke Spekenbrink-Spooren; Rob G H H Nelissen; Reinoud W Brouwer
Journal:  Acta Orthop       Date:  2022-02-14       Impact factor: 3.717

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.